Site of action of development of partial tolerance to morphine in cats

The vasopressin deficient Brattleboro rats: a natural knockout model used in the search for CNS effects of vasopressin

Behavioral neuroscience is using more and more gene knockout techniques to produce animals with a specific deletion. These studies have their precedent in nature. A mutation may result in a limited genetic defect, as seen in the vasopressin (VP) deficiency in the Brattleboro rat. The mutation is in a single pair of autosomal loci, and the sequences of VP gene from wild-type and homozygous Brattleboro rats are identical except for a single nucleotide deletion in the second exon. The deletion results in the synthesis of an altered VP precursor that is unable to enter the secretory pathway. The genetic disturbance results in a central diabetes insipidus comparable to that found in humans. Starting with our work during the early 1970s we found that the genetic defect in the availability of VP causes deficits in central nervous system (CNS) functions. Behavioral processes from cognition to drug tolerance appeared to be disturbed by the absence of VP, but not all behaviors are affected. The specificity of the absence of VP in causing behavioral deficits is shown in many cases. However, certain deficits are due to genetic factors other than the deletion of the VP gene. The picture is further complicated by differences in testing conditions, the absence of proper controls, i.e. heterozygous and wild-type Brattleboro rats, sex, compensation phenomena, and the absence of neuropeptides co-localized with VP. Interestingly, an age dependent spontaneous shunt to a heterozygous phenotype in vasopressinergic neurons might also compensate for the disturbance. Accordingly, findings in knockout animals should be interpreted with caution. One should realize that brain functions are modulated by multiple neuropeptides and that neuropeptides possess multiple CNS effects.

Role of oxytocin in the neuroadaptation to drugs of abuse

Oxytocin (OXT), a neurohypophyseal hormone, has a wide range of behavioral effects outside its classic peripheral endocrine functions. OXT involvement in adaptive central nervous system processes has been demonstrated as an inhibitory, amnestic action on learning and memory in different paradigms. Because adaptation and learning are likely to be involved in the neural events leading to drug tolerance and dependence, the question logically arose whether OXT is able to influence the development of tolerance of and dependence on abused drugs. In this review, we summarize our results on the effects of OXT on opiate (including morphine, heroin, and the endogenous opiates beta-endorphin and enkephalin) tolerance and dependence, heroin self-administration, psychostimulant-induced behavioral changes, and behavioral tolerance and sensitization. The sites and mechanisms of action and the possible physiological role of OXT are also discussed. In the first part of this review the effects of exogenously administered OXT on both the acute and chronic behavioral effects of opiates and psychostimulants have been summarized. OXT inhibited the development of tolerance to morphine, heroin, beta-endorphin, and enkephalin, OXT also inhibited the development of cross-tolerance between the predominantly mu-agonist heroin and the predominantly delta-agonist enkephalin in mice. Naloxone-precipitated morphine withdrawal syndrome was also attenuated by OXT. Heroin self-administration was decreased by OXT administration in heroin-tolerant rats. OXT inhibited cocaine-induced exploratory activity, locomotor hyperactivity, and stereotyped behavior in rats and in mice. Behavioral tolerance to cocaine was also attenuated by OXT. On the contrary, OXT stimulated the development of behavioral sensitization to cocaine. OXT did not alter the stereotyped behavior induced by amphetamine. In the second series of experiments, the sites of action of OXT on drug-related behavior were investigated. Intracerebro-ventricular (ICV) and intracerebral (IC) administration of an OXT-receptor antagonist inhibited the effects of peripherally administered OXT on morphine tolerance, heroin self-administration, and cocaine-induced sniffing behavior. This suggests the central, intracerebral location of OXT target sites. Local IC microinjection of OXT in physiological doses into the posterior olfactory nucleus, tuberculum olfactorium, nucleus accumbens, central amygdaloid nucleus, and the hippocampus inhibited the development of tolerance to and dependence on morphine as well as cocaine-induced sniffing behavior and tolerance to cocaine. The physiological role of endogenous OXT in acute morphine tolerance has also been demonstrated, since OXT antiserum (ICV) and OXT-receptor antagonist (injected into the basal forebrain structures) potentiated the development of morphine tolerance. Finally, we investigated the possible mechanisms of action of OXT on drug related behavior. Both morphine tolerance and dependence, and cocaine administration, increased dopamine utilization in the mesencephalon and in the nucleus accumbens, respectively. OXT treatment decreased the alpha-methylparatyrosine-induced dopamine utilization in the mesencephalon and in the nucleus accumbens-septal complex. Chronic OXT treatment decreased the number of apparent binding sites of dopamine in the basal forebrain area. It also inhibited a cocaine-induced increase in dopamine utilization in the nucleus accumbens, but not in the striatum. In light of this information, it appears that OXT inhibits the development of opiate tolerance, dependence, and self-administration as well as the acute behavioral actions of and chronic tolerance to cocaine. This suggests the possible role of this neuropeptide in the regulation of drug abuse. Therefore, OXT may act as a neuromodulator on dopaminergic neurotransmission in limbic-basal forebrain structures to regulate adaptive CNS processes leading to drug addiction.

Central functions of oxytocin

Oxytocin, the peptide well-known for its hormonal role in parturition and lactation, is present in several extrahypothalamic brain areas besides the neurohypophyseal system. The peptide is found in neurons which send their projections to brain areas containing specific oxytocin-binding sites. Oxytocin is also released from its synapses in a calcium-dependent fashion and may be the precursor of potent behaviorally active neuropeptides. These findings suggest that this ancient neuropeptide acts as a neurotransmitter in the central nervous system. We have attempted to review the most recent behavioral, morphological, electrophysiological and neurochemical studies providing evidence that oxytocin plays an important role in the expression of central functions, such as maternal behavior, sexual behavior (penile erection, lordosis and copulatory behavior), yawning, memory and learning, tolerance and dependence mechanisms, feeding, grooming, cardiovascular regulation and thermoregulation.

Morphine and specific changes in the sensitivity of noradrenergic receptors within the "limbic" part of the feline caudate nucleus: a behaviour study

The present study describes the behaviour effects of intracerebral injections of the noradrenergic (NE) agonist oxymetazoline and the NE antagonist phentolamine into the "limbic" part of the caudate nucleus of cats primed 24 hr earlier and/or treated acutely with morphine (5 mg/kg, IP). Drug-induced changes in the morphine-specific behaviour served as dependent variables. Experiments were performed during two different periods of the year, each of them marked by a characteristic sensitivity of alpha-like NE receptors to NE agents, viz. the so-called NE "antagonist" period during which the NE receptors were sensitive to the NE antagonist phentolamine and the so-called NE "agonist" period during which the NE receptors were sensitive to NE and the NE agonist oxymetazoline. The present study demonstrates that morphine reversed the initial sensitivity to oxymetazoline respectively insensitivity to phentolamine in animals tested in the NE "agonist" period. In animals tested in the NE "antagonist" period morphine did not reverse the initial insensitivity to oxymetazoline resp. sensitivity to phentolamine. Furthermore, evidence is provided that the initial sensitivity to NE agents did not conspicuously determine the animal's response to the acute administration of morphine. The data are discussed in view of the concept that the firing rate of NE fibres determines the actual sensitivity of presynaptic and postsynaptic NE receptors to NE agonists and antagonists.

Intraseptally injected opiate agents: effects on morphine-induced behaviour of cats

Behavioural effects of intraseptally administered opiate agents were analyzed in cats pretreated with an intraperitoneal injection of morphine. In this way, it became possible to investigate (1) the involvement of septal opiate receptors in the behavioural response of cats to systemic administration of morphine, and (2) the pharmacological character of septal opiate receptors. The following results were obtained with intraseptal injections 15-16 min after intraperitoneal morphine: (1) naloxone decreased frequencies of head and limb movements, and (2) morphine was ineffective. The following results were obtained with intraseptal injections 40-41 min after intraperitoneal morphine: (1) beta-endorphin and, to a lesser extent, fentanyl increased frequencies of locomotor patterns, (2) morphine and Met-enkephalin were ineffective, (3) naloxone and naltrexone decreased frequencies of locomotor patterns in a dose-dependent way, (4) naloxone and naltrexone antagonized the effects of beta-endorphin and fentanyl, and (5) morphine did not attenuate the effect of naloxone. The intraseptal injections affected only the frequencies of the systemically evoked behaviour patterns; the nature of the behaviour patterns remained unchanged. It is concluded that (1) systemically administered morphine does not affect behaviour via a direct action on septal opiate receptors, and (2) the receptors mediating the septally evoked effects are most probably epsilon-type opiate receptors. The hypothesis is put forward that systemic administration of morphine results in an increased release of beta-endorphin from hypothalamo-septal neurons and, as a consequence, changes the beta-endorphin activity at the epsilon-type opiate receptors in the septum.

Interaction between des-glycinamide9-[Arg8]vasopressin and serotonin on ethanol tolerance

Sham and electrolytic lesions of the dorsal, median, and dorsal + median raphe nuclei were made in different groups of rats. One week later, daily oral treatment with ethanol (5 g/kg p.o. for 25 days) was started. This treatment produced tolerance to the hypothermic and motor impairing (moving belt test) effects of ethanol. On day 26, ethanol was stopped and subcutaneous injection of either 10 micrograms of des-Gly9-[Arg8]vasopressin (DGAVP) in saline or saline alone was started. The retention of tolerance to ethanol was measured at 3-day intervals for both hypothermia and motor-impairment. In sham-saline groups, disappearance of tolerance took 3 days for the hypothermic effect, and 9 days for the motor-impairment effect. Tolerance to both effects, however, was still observed after 9 days in DGAVP-treated rats with either sham or dorsal raphe lesions. Peptide treatment, on the other hand, failed to maintain tolerance in rats with median or median + dorsal raphe lesions. These results suggest that an intact mesolimbic serotonin pathway is necessary for the action of DGAVP on the retention of ethanol tolerance.

Presence of a particular subpopulation of dopamine receptors within the septal nuclei: a behavioural study on cats

The behavioural effects of intraseptal administration of dopaminergic drugs (apomorphine, haloperidol, (3,4-dihydroxy-phenylamino)-2-imidazoline (DPI), ergometrine and dopamine) and alpha-noradrenergic drugs (oxymetazoline, noradrenaline and phentolamine) were analysed in cats pretreated with morphine (5 mg/kg, i.p.). Changes in frequencies of stereotyped locomotor patterns were used for statistical evaluation of drug-induced effects. Taking advantage of the specificity of the drugs mentioned, a distinction could be made between effects mediated via excitation-mediating dopamine (DAe), inhibition-mediating dopamine (DAi) and alpha-noradrenaline (alpha-NA) receptors. Intraseptal injection of the DAi agonist DPI resulted in a decrease in the frequency of stereotyped locomotor patterns. This effect was dose-dependent and mimicked by that of intraseptally applied dopamine but not of any of the other drugs. Moreover, intraseptal injection of the DAi antagonist ergometrine inhibited the effect of DPI. The DAe agonist apomorphine as well as the DAe antagonist haloperidol remained ineffective when applied in low doses. The alpha-NA antagonist phentolamine and a rather high dose of haloperidol produced a slight but significant increase in the frequency of locomotor patterns; intraseptally applied oxymetazoline counteracted the phentolamine-induced effect. It is concluded that the septal nuclei of cats contain functionally active, alpha-NA receptors as well as functionally active, dopamine (DA) receptors having pharmacological properties identical to those of DA receptors present within the mesolimbic structures such as the nucleus accumbens: the so-called inhibition-mediating DAi receptors.

Effects of peptides related to neurohypophyseal hormones on ethanol tolerance

Mice were rendered tolerant to the hypothermic effect of ethanol by forcing them to inhale ethanol vapor for 3 days. One day after withdrawal, tolerance was assessed by determining the response of the mice to an acute 3 g/kg IP challenge dose of ethanol. Thirty minutes before the injection of ethanol, saline or peptide solution was SC injected. The peptides studied were des-Gly9-Arg8-vasopressin (a peptide with reduced peripheral endocrine activities), oxytocin, and analogs and fragments of these peptides. None of the peptides, with the possible exception of oxytocin, affected body temperature in naive animals or the acute hypothermic response to ethanol in non-tolerant mice. Des-Gly9-Arg8-vasopressin enhanced the expression of tolerance to ethanol hypothermia; shorter fragments of vasopressin did not share this effect. Oxytocin attenuated the expression of tolerance but this may been due to an interaction with the acute effects of ethanol.

Behavioral changes produced in the cat by acute and chronic morphine injection and naloxone precipitated withdrawal

To address the issue of feline manic responses to morphine, studies were designed to examine the effects of low doses of intravenous morphine on cat behavior with emphasis placed on motor activity changes. An adaptation of an existing scoring system was used in an effort to quantify and describe behavioral patterns or shifts in activity patterns occurring during a cycle of addiction. The acute administration of 1, 2 or 4 mg/kg of morphine induces a response pattern characterized by sitting with fixed staring. An increase in motor activity with dose was also observed. When naloxone was administered prior to morphine injection all behavioral changes normally elicited by morphine were blocked completely. After 7 days of daily morphine injections certain changes in activity profiles occurred, indicating that some degree of tolerance although not complete, was beginning to occur by this time. Naloxone administered to cats maintained for 12 days on1, 2 or 4 mg/kg/day consistently produced a number of withdrawal signs including wet-dog shakes and a catatonic-like posturing. This is the first report describing behavioral responses of the cat during a complete cycle of addiction to low doses of morphine. We not only found that morphine will elicit definite quantifiable changes in behavior in the absence of any feline mania but that cats become readily dependent on these low doses of morphine as evidenced by a characteristic naloxone precipitated withdrawal syndrome.

Methadone-induced changes in the visual evoked response recorded from multiple sites in the cat brain

Visual evoked responses (VERs) and EEG were recorded following the i.p. administration of five doses of methadone (0.5--4 mg/kg) to 12 adult cats, which were implanted with cortical and subcortical electrodes. Additional cats, subjected to the same drug regimen, were used to evaluate plasma methadone concentrations. Doses of methadone that produced plasma concentrations between 80 and 190 ng/ml differentially affected VERs recorded from cortical and subcortical sites. Of the subcortical structures evaluated, the limbic system, specifically the hippocampus, was the most sensitive to the effects of the drug. These effects appeared to be primarily depressant. Responses recorded from the reticular formation and centromedian were affected only by the highest dose of methadone, while VERs recorded from cortical sites were reliably altered following the two highest doses and appeared to reflect both excitation and depression. Behavioral changes, however, were clearly evidenced in some cats at lower doses of methadone. Therefore, the data suggest (1) that those structures evaluated electrophysiologically did not reflect the full force of the drug's action as evidenced by its effect on behavior, (2) that cortical and subcortical recording sites have differential sensitivities, and (3) that one clearly defined, principal size of action of methadone is absent in the cat.

Locus coeruleus and substantia nigra: involvement in morphine-induced behavior

Cats pretreated with morphine (5 mg/kg, IP) received naloxone into the area of the locus coeruleus (LC) or the area of the substantia nigra (SN). The LC-treated animals stopped the morphine-induced stereotyped behavior and showed normal but hyperactive behavior. The SN-treated animals, however, ceased their movements of the head and the forelegs, adopted a rigid posture with extended forelegs and became hypoactive. It is concluded that both the LC area, which contains noradrenergic cell bodies, and the SN area, which contains dopaminergic cell bodies, are sites of action of morphine on behavior.